Table 1. Cotreatment with LBH589 and/or... | American Society of Hematology

Table 1.

Cotreatment with LBH589 and/or 1.7-AAG-induces more loss of cell viability than either agent alone in primary AML or CML-BC cells.

		Cell death, %
		nM, 17-AAG			nM, LBH589			10 nM, LBH589 + nM, 17-AAG		50 nM, LBH589 + nM, 17-AAG
Patient no.	Control	250	1000	10	50	250	1000	250	1000
CML-BC cells
1	2.1	2.8	9.1	12.9	37.0	42.3	49.0	55.7	59.3
2	4.5	9.6	38.0	38.5	56.0	48.5	63.8	63.0	74.0
3	4.0	5.8	21.0	16.4	19.9	53.0	63.0	61.5	76.0
4	10.1	16.9	24.1	18.8	28.0	30.0	38.8	39.8	42.4
5	9.3	15.8	26.3	22.7	44.9	33.1	49.1	44.7	50.3
AML cells
1	5.6	12.2	43.7	17.4	45.8	46.5	58.9	63.3	66.2
2	13.1	28.5	58.1	34.7	55.9	54.3	71.6	63.6	73.2
3	7.6	21.7	39.1	19.6	39.7	44.1	53.7	60.9	67.2
4	9.4	26.3	46.4	31.3	51.4	57.6	69.4	75.6	79.1

		Cell death, %
		nM, 17-AAG			nM, LBH589			10 nM, LBH589 + nM, 17-AAG		50 nM, LBH589 + nM, 17-AAG
Patient no.	Control	250	1000	10	50	250	1000	250	1000
CML-BC cells
1	2.1	2.8	9.1	12.9	37.0	42.3	49.0	55.7	59.3
2	4.5	9.6	38.0	38.5	56.0	48.5	63.8	63.0	74.0
3	4.0	5.8	21.0	16.4	19.9	53.0	63.0	61.5	76.0
4	10.1	16.9	24.1	18.8	28.0	30.0	38.8	39.8	42.4
5	9.3	15.8	26.3	22.7	44.9	33.1	49.1	44.7	50.3
AML cells
1	5.6	12.2	43.7	17.4	45.8	46.5	58.9	63.3	66.2
2	13.1	28.5	58.1	34.7	55.9	54.3	71.6	63.6	73.2
3	7.6	21.7	39.1	19.6	39.7	44.1	53.7	60.9	67.2
4	9.4	26.3	46.4	31.3	51.4	57.6	69.4	75.6	79.1

Primary IM refractory CML-BC or AML cells with FLT-3 with ITD or point mutation were treated with the indicated concentrations of LBH589 and/or 17-AAG for 48 hours and the percent of nonviable cells was determined by the trypan blue exclusion method. The values represent the mean of 2 experiments performed in duplicate.

View Large

This Feature Is Available To Subscribers Only